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Background: During wound healing processes fibroblasts account for wound closure by adopting a contractile
phenotype. One disease manifestation of COPD is emphysema which is characterized by destruction of alveolar
walls and our hypothesis is that fibroblasts in the COPD lungs differentiate into a more contractile phenotype as a
response to the deteriorating environment.
Methods: Bronchial (central) and parenchymal (distal) fibroblasts were isolated from lung explants from COPD patients
(n = 9) (GOLD stage IV) and from biopsies from control subjects and from donor lungs (n = 12). Tissue-derived
fibroblasts were assessed for expression of proteins involved in fibroblast contraction by western blotting whereas
contraction capacity was measured in three-dimensional collagen gels.
Results: The basal expression of rho-associated coiled-coil protein kinase 1 (ROCK1) was increased in both centrally and
distally derived fibroblasts from COPD patients compared to fibroblasts from control subjects (p< 0.001) and (p<0.01),
respectively. Distally derived fibroblasts from COPD patients had increased contractile capacity compared to control
fibroblasts (p< 0.01). The contraction was dependent on ROCK1 activity as the ROCK inhibitor Y27632 dose-dependently
blocked contraction in fibroblasts from COPD patients. ROCK1-positive fibroblasts were also identified by
immunohistochemistry in the alveolar parenchyma in lung tissue sections from COPD patients.
Conclusions: Distally derived fibroblasts from COPD patients have an enhanced contractile phenotype that is
dependent on ROCK1 activity. This feature may be of importance for the elastic dynamics of small airways and the
parenchyma in late stages of COPD.
Keywords: Chronic obstructive pulmonary disease, Contractility, Emphysema, Fibroblast/myofibroblast, Rho-associated
coiled-coil protein kinase 1Background
Chronic obstructive pulmonary disease (COPD) is char-
acterized by a reduction in respiratory airflow that is not
possible to fully normalize [1]. Several factors contribute
to the reduced airflow. In central and small airways epi-
thelial dysregulation results in impaired mucocilliary* Correspondence: oskar.hallgren@med.lu.se
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reproduction in any medium, provided the orclearance, over-production of mucus, squamous cell
metaplasia and subepithelial fibrosis [2,3]. Degradation
of alveolar walls (emphysema), a hallmark of COPD, lim-
its the area of gas exchange and reduces the elastic re-
coil. Cigarette smoke is undoubtedly the most
contributing cause to these changes, as a majority of
COPD patients have a history of heavy smoking. The in-
flammatory effect of cigarette smoke has been exten-
sively examined and includes accumulation of
inflammatory cells [2,4,5]. Inflammation per se can be
regarded as part of a wound healing process. However, if
the inflammatory stimuli persist, the process mayl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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alterations can be observed [6]. Fibroblasts are key
players in wound healing as they are the main producer
of extracellular matrix (ECM) and may adopt a contract-
ile phenotype to promote wound closure [7,8]. A num-
ber of factors have been implicated in controlling
fibroblast differentiation, including the growth factor
TGF-β [9]. The compliance of the tissue is another de-
terminant of the differentiation process [10]. The hall-
mark of a contractile fibroblast is a high expression of
proteins involved in the contractile machinery which
results in the formation of stress fibers [11]. The rho/
ROCK pathway has been suggested to be a sensor of tis-
sue compliance. As a result of increased tissue stiffness
it may stimulate phosphorylation of myosin light chain
kinase (MLCK) and subsequent assembly of stress fibers
[11-13]. Fibroblasts contraction is also dependent on the
expression of α-smooth muscle actin (α-SMA) [14].
Interestingly, it has been suggested that there exist dif-
ferent subsets of fibroblasts in central airways and in al-
veolar parenchyma, characterized by differences in
morphology, production of ECM proteins and in the ex-
pression of α-SMA [15,16]. In a previous study we
reported that these differences also included the produc-
tion of proteoglycans [17]. In addition, the fibroblast
phenotypes were altered in fibroblasts isolated from se-
vere COPD patients.
The hypothesis of this study was that the altered pheno-
types of centrally and distally derived fibroblasts from
COPD patients also extend to their contractile properties.
We especially wanted to investigate if the activity of rho/
ROCK could account for such changes.
Methods
Patients
Patients (n = 9) suffering from very severe COPD
(GOLD stage IV) who were undergoing lung transplant-
ation at Lund University Hospital were included in the
study [17]. The patients had stopped smoking at least
6 months before the lung transplantation. All patients
were given a combination of different medicines. All of
them were given glucocorticoids on regular basis. Con-
trol subjects were recruited from two different sources.
First, non-smoking volunteers (n = 8) with no clinical
history of any lung diseases were included in the study
[18]. Written consent was obtained from all subjects.
Second, lung explants from healthy donors (n = 4) with
no history of lung disease were also included. Lungs
were to be used for transplantation but could instead be
included in this study as no matched recipients were
available at that moment. In these cases written consent
was obtained from their closest relatives. This study was
approved by the Swedish Research Ethical Committee in
Lund (FEK 91/2006, FEK 213/2005 and FEK 413/2008).Isolation of cells
Fibroblasts were isolated from explants from COPD
patients as previously described [19]. Control fibroblasts
were obtained from two different sources: from bron-
chial and transbronchial biopsies and explants from
donors in situation when the lungs were not used for
transplantation. Biopsies from control subjects were im-
mediately after sampling transferred to cell culture
medium (DMEM supplemented with 10% FBS, Genta-
micin, PEST, and Amphotericin B (all from Gibco BRL,
Paisley, UK)). After rinsing, bronchial and parenchymal
pieces from biopsies were chopped into small pieces that
were allowed to adhere to the plastic of cell culture
flasks for 4 h and were then kept in cell culture medium
in 37°C cell incubators until outgrowth of fibroblasts
were observed. Bronchial and parenchymal fibroblasts
were then referred to as centrally and distally derived
fibroblasts, respectively.
Lung explants from COPD patients and donor lungs
were dissected directly after removal from COPD
patients and donors. Lung specimens were then immedi-
ately transferred to cell culture medium. Bronchial tissue
was collected from the luminal side from the same
localization as where bronchial biopsies were taken. Al-
veolar parenchymal specimens from explants were col-
lected 2–3 cm from the pleura in the lower lobes, i.e.
from the same location as where transbronchial biopsies
were taken. Vessels and small airways were removed
from the peripheral lung tissues. Bronchial and paren-
chymal specimens were chopped into small pieces and
then treated as the biopsy material described above. All
experiments were performed in passage 3–7. Within this
range we could not see any correlation between passage
number and any of the investigated parameters. The
mean passage number when experiments were per-
formed was 5.3 for centrally derived fibroblasts from
control subjects, 4.6 for centrally derived fibroblasts
from COPD patients, 5.3 for distally derived fibroblasts
from control subjects and 5.3 for distally derived fibro-
blasts from COPD patients. The cell cultures were con-
tinuously stained with antibodies against vimentin and
prolyl-4 hydroxylase to verify the mesenchymal identity
and to estimate the purity. In the few cases when the
cellular staining was less clear then the cell morphology
was verified to be fibroblast-like and representative for
the culture as a whole.
Western blot
Cells were grown under standardized conditions and
whole cell lysates were prepared using lysis buffer
(50 mM Tris–HCl, 500 mM NaCl, 1% NP-40, 10% gly-
cerol, 10 mM MgCl2 pH 7,4) containing the protein in-
hibitor complete mini (1 mM PMSF, 1 μg/ml Aprotinin,
1 μg/ml Pepstatin, 1 μg/ml Leopeptin, Roche, Manheim,
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and equal amounts of protein, 10 μg, were loaded and
separated by electrophoresis on 4–12% Bis-Tris Gels
(Invitrogen, Gibro, Carlsbad, CA). The proteins were
blotted to PVDF membranes (Immobilon-P Transfer
Membrane, Millipore Corporation, Billerica, MA). Mem-
branes were incubated with antibodies against ROCK1
(Abcam, Cambridge, UK) , α-SMA (Abcam, Cambridge,
UK), Rho-A (Santa Cruz Biotechnology, Inc. Santa Cruz,
CA), and GAPDH (Santa Cruz Biotechnology, Inc.
Santa Cruz, CA). Bound antibodies were visualized by
Dy-light 700 and 800 nm conjugated secondary anti-
bodies (Cell Signaling Technology Inc., Boston, MA).
The fluorescence signal was detected on OdysseyW FC
imaging system (LI-COR Biosciences, Lincoln, NE). Ex-
posure times were standardized so that all samples were
treated the same way for each antibody.Phalloidin staining
Fibroblasts (7000/well) grown overnight in 4-well cham-
ber slides were fixed in 4% formaldehyde for 15 minutes
and then permeabilized 0.1% Triton X for 10 minutes.
Cells were then blocked in 2% BSA-TBS for 30 minutes
and incubated with Alexa-fluor 488-conjugated phal-
loidin (Molecular Probes Invitrogen, Eugene, OR) for
30 minutes. Glasses were mounted using mounting
media (Dako, Glostrup, Denmark). Cells were photo-
graphed using a TE2000-E fluorescence microscope
(Nikon, Tokyo, Japan) equipped with a DXM1200C
camera (Nikon).Immunohistochemistry
Immunostaining of fibroblasts
Fibroblasts (7000/well) grown overnight on chamber
slides were fixed in 4% formaldehyde for 15 minutes and
then permeabilized with 0.1% Triton X for 30 minutes.
Cells were blocked in 2% BSA-TBS containing 5% goat
serum (Vector laboratories, Burlingame, CA). Cells
were incubated with primary antibodies: monoclonal
mouse antibody against Prolyl 4-Hydroxylase (Acris
antibodies, Hiddenhausen, Germany), monoclonal
mouse IgM antibody against Vimentin (Santa Cruz
Biotechnology, Santa Cruz, CA), polyclonal rabbit
antibody against ROCK1 (Abcam, Cambridge, UK),
monoclonal IgG and antibody against SM22-alpha
(Abcam, Cambridge, UK), and with secondary antibodies:
Alexafluor 488-conjugated goat anti-mouse antibody and
Alexafluor 555-conjugated goat anti-mouse antibody
(both from Molecular Probes Invitrogen, Eugene, OR). To
stain nuclei, cells were incubated with DAPI (Molecular
Probes Invitrogen, Eugene, OR). Glasses were mounted
with mounting media (Dako, Glostrup, Denmark). Cells
were photographed using a TE2000-E fluorescencemicroscope (Nikon, Tokyo, Japan) equipped with a
DXM1200C camera (Nikon).
Tissue staining
Tissue from adjacent locations as where pieces for cell
isolations were taken was fixed in 4% paraformaldehyde
and embedded in paraffin. From each block, sections
5 μm in thickness were generated. Sections were depar-
affinized, rehydrated and pre-treated to make epitopes
accessible for antibodies. Endogenous peroxidase ac-
tivity was blocked in 3% hydrogen peroxidase (Merck,
Damstadt, Germany) followed by a 30 minutes block with
2% BSA-TBS containing 5% serum raised in the same
species as the secondary antibodies used. Furthermore,
endogenous avidin and biotin binding sites were blocked
(Vector avidin/biotin blocking kit, Vector laboratories,
Burlingame, CA) according to the manufacturer’s proto-
col. Sections were incubated with primary antibodies:
rabbit polyclonal antibody against ROCK1 (Abcam,
Cambridge, UK), mouse monoclonal antibody against
Vimentin (Santa Cruz Biotechnology, Santa Cruz, CA)
and mouse monoclonal antibody against prolyl-4 hydroxy-
lase (Acris antibodies, Hiddenhausen, Germany). This
was followed by incubation with secondary antibodies:
biotin-conjugated goat anti-rabbit (Vector laboratories,
Burlingame, CA), biotin-conjugated horse anti-mouse
(Vector laboratories, Burlingame, CA). Sections were
incubated with avidin and biotin (Vector laboratories,
Burlingame, CA) according to the manufacturer’s
instructions and were developed with DAB (Vector la-
boratories, Burlingame, CA) to visualize bound anti-
bodies and then counterstained with Mayer’s
hematoxylin. Alternatively, sections were double-stained
with primary antibodies as mentioned above and then
incubated with Alexa-flour 555 and 647 conjugated sec-
ondary antibodies (Molecular Probes Invitrogen, Eugene,
OR). To stain nuclei, cells were incubated with DAPI
(Molecular Probes Invitrogen, Eugene, OR). Sections
were photographed using a TE2000-E fluorescence
microscope (Nikon, Tokyo, Japan) equipped with a
DXM1200C camera (Nikon, Tokyo, Japan).
Fibroblast contraction assay
The gels were prepared using a modified form of a
protocol that has previously been described [20]. Briefly,
96-well tissue culture plates (Cellstar, Monroe, NC) were
coated with 1% BSA overnight and were then washed
with PBS. Neutral collagen solution was prepared by
mixing 2x DMEM, supplemented with 4% FCS and 10%
Glutamine, Collagen type-I solution (PureCol, Inamed
Biomaterials, Fremont, CA) and 0.2 M HEPES buffer,
pH 8.0 in the volume relation 5:4:1. Fibroblasts, sus-
pended in DMEM (1 × 106 cells/ml) were added to colla-
gen solution in the relation 1:9 (v/v). The final cell
Table 1 COPD patients and control subjects in the study
Characteristics Controls COPD
No. 8 + 4* 9
Age (range) 29* (23–41) 62 (53–66)
Pack years (range) 1* (0–8) 39 (25–60)
Gender, M/F in % 42/58 33/67
Lung function
FEV1 4.1* (3.2–5.4) 0.55 (0.4–0.9)
FEV1 % predicted 102.6* (84–116) 19.3 (14–24)
FVC 5.0* (4.0–6.4) 2.0 (1.3–2.8)
FEV1 % predicted/FVC 21* (17–25) 30 (20–39)
DLco m 1.4 (1.4–1.5)†
DLco % predicted m 24 (14–42)}
*Values are only from 8 of the control subjects. The other 4 subjects were lung
donors with no former history of lung disease. Three out of four had the age
interval between 46 and 65 years old and one between 31–45 years old. One
of them was a former smoker with a smoking history of 7.5 pack years. There
was no other lung function characteristics available for these individuals.
† Only values from 5 patients. } Only values from 6 patients. m denotes that
data is missing. Data is presented as mean (range).
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of collagen in the contraction gels was 1.1 mg/ml in
DMEM with a physiological ionic strength of 1 ×DMEM
(pH 7.4) containing 0.4% FCS and 1% Glutamine. 100 μl
cell/collagen solution were added to each well and the
collagen gels were polymerized for 1 hour at 37°C.
After polymerization 100 μl of DMEM supplemented
with 0.4% FCS and 1% Glutamine was gently added
to each well. Gels were released with a spatula 4 hour
after polymerization and were photographed using a
camera (Sony, Tokyo, Japan). The gel area at this
point was used as the initial area. The gel area was
then monitored over time and was compared to the
initial area. All gel contraction experiments are the
mean of triplicate measurements. In indicated cases
Y27563 or blebbistatin was added to cell suspensions
just before they were mixed with the collagen
solution.
Cytoxicity assay
The cytotoxic effect of ROCK inhibitor Y27632 and the
Myosin II inhibitor blebbistatin was assessed by trypan
blue exclusion. Cells were incubated for 24 hours in the
presence of the inhibitors. Trypan blue (Gibco BRL,
Paisley, UK) was added to wells and a minimum of 250
cells were counted in each well and the number of living
(non-stained) or dead (blue) cells were recorded. A
minimum of 4 wells were used for each concentration of
the inhibitors.
Statistics
Data are expressed as mean± SEM. The Mann–Whitney
test was used to compare statistical differences between
two groups. The Wilcoxon signed rank test was used to
perform a paired comparison of the effect of the inhibi-
tors. Comparison of the inhibitory effect of Y27632 and
blebbistatin on the two cell types was done by compar-
ing the fold change with/without the inhibitors. The
ratios were then compared with the Mann–Whitney test.
The comparison between the two inhibitors was calcu-
lated as (Y27632 - untreated) / (blebbistatin - untreated)
for the individual cell types and the groups were then
compared with the Mann–Whitney test. In some cases
it was not possible to establish cell cultures because
there was no outgrowth of fibroblasts. In other cases
there were few cells in a culture with low proliferative
potential. In these cases there were not cells enough for
all experiments and therefore the number of patients or
controls in each experiment varies. However, no avail-
able data have been excluded from the measurements
and the statistical analysis. Differences were considered
significant at p < 0.05. All analyses were performed using
GraphPad Prism software version 4.00 (GraphPad Soft-
ware, San Diego, CA).Results
Clinical and demographic features
Characteristics of included COPD patients (n = 9) and
control subjects (n = 12) are shown in Table 1. 3 out of
9 were males the COPD group while 5 out of 12 were
males in the control group. Predicted FEV1 was 19.9% in
COPD patients and 102.6% for control subjects. All the
COPD patients were ex-smokers with a heavy smoking
burden whereas 11 of the controls were never smokers
and one was an ex-smoker with 8 pack years.Phenotypes of centrally and distally derived fibroblasts
Contractile properties were evaluated in centrally and
distally derived fibroblasts from control subjects and
COPD patients. Stress fibers were visualized by phal-
loidin staining as shown in Figure 1A-D. Distally derived
fibroblasts from COPD patients had a phalloidin staining
pattern with parallel fibers attached to their lamellipodia
typical for contractile cells. This was contrasted with the
staining pattern in distally derived fibroblasts from con-
trol subjects and centrally derived fibroblasts from
COPD patients and control subjects. To further evaluate
the contractile properties of the cells the ability to con-
tract three-dimensional collagen gels was assessed. Dis-
tally derived fibroblasts from COPD patients contracted
the gels significantly more than the other cell types at all
investigated time points (Figure 2A). After 24 hours dis-
tally derived fibroblasts had contracted the gels signifi-
cantly more (0.49 ± 0.05) than centrally derived
fibroblasts from COPD patients (0.70 ± 0.04) (p < 0.01)
and also against distally derived fibroblasts from control
subjects (0.72 ± 0.01) (p < 0.05), (Figure 2B).
Figure 1 Stress fiber staining in isolated fibroblasts. Stress fibers were visualized in centrally (A and B) and distally (C and D) derived
fibroblasts from control subjects (A and C) and COPD patients (B and D) by staining with phalloidin that binds to F-actin. Contractile cells have
parallel fibers attached to their lamellipodia as is indicated by arrowheads in (D) Other cell types do not have this feature to the same extent.
Scale bars represent 50 μm.
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We next examined the expression of proteins known to be
involved in fibroblast contraction: ROCK1, α-SMA and
Rho A to elucidate the molecular mechanism for the
increased contractility (Figure 3 A-C). Distally derived
fibroblasts from COPD patients had significantly higher
ROCK1 expression (0.09 ± 0.008) than distally derived
fibroblasts from control subjects (0.02 ± 0.002) (p <0.001).
Centrally derived fibroblasts from also had significantly
higher ROCK1 expression (0.03 ± 0.006) than centrally
derived fibroblasts from control subjects (0.01 ± 0.002)
(p <0.01). In addition, ROCK1 expression in distally
















Figure 2 Collagen gel contraction. (A) The contractile potential of the is
by comparing gel areas of each time point by the initial gel areas. Each po
of isolated fibroblasts after 24 hours compared to the initial area. Open sym
symbols fibroblasts isolated from lung biopsies. **P < 0.01.subjects were significantly higher than their respective cen-
trally derived counter-parts (p < 0.01 for both comparisons).
There was a trend to increased α-SMA expression in dis-
tally derived fibroblasts from control subjects compared
to centrally derived fibroblasts (p < 0.054) and a similar
trend was observed for distally and centrally derived
fibroblasts from COPD patients (p < 0.055). Distally
derived fibroblasts from COPD patients had significantly
higher Rho A expression (1.63×10-5 ± 3.45×10-6) com-
pared to centrally derived fibroblasts from COPD patients
(5.41×10-6 ± 1.30×10-6) (p < 0.05). The cellular expres-
sion of ROCK1 in distally derived fibroblast from COPD
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Figure 3 Expression of proteins involved in fibroblast
contraction. Cell extracts from centrally and distally derived
fibroblasts from control subjects and COPD patients were
immunoblotted using antibodies against ROCK1 (A), α-SMA (B),
RhoA (C), and GAPDH. Blotted bands were quantified with
morphometry and values are presented as the intensity of each
band relative to the intensity of the loading control: GAPDH. Photos
show representative bands. **P < 0.01 and *** < 0.001.
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of the fibroblasts was verified by using antibodies against
vimentin, a member of intermediate filaments in mesen-
chymal cells and prolyl-4 hydroxylase, an enzyme involved
in collagen synthesis (Figure 4 B-C).Role of ROCK and myosin II on fibroblast contraction
We next investigated the contribution of ROCK1 to con-
traction by using the selective ROCK inhibitor Y27632
(Table 2). The concentrations that were used had no effecton cell viability as shown in Figure 5 F. A dose-dependent
response was recorded for centrally derived fibroblasts
from control subjects (p < 0.05) and for distally derived
fibroblasts from COPD patients (p < 0.01) (see Table 2).
The inhibitor had less effect on distally derived fibroblasts
from control subjects and centrally derived fibroblasts from
COPD patients. However, the 10 μM dose significantly
inhibited contraction compared to untreated cells in cen-
trally derived fibroblasts from control subjects (p < 0.01)
and distally derived fibroblasts from both control subjects
and COPD patients (p < 0.001 for both) when the analysis
was paired as shown in Figure 5A and C. The inhibitory ef-
fect defined as the fold change with and without addition
was greater in fibroblasts from COPD patients (p < 0.001)
than in fibroblasts from control subjects The myosin II in-
hibitor, blebbistatin, dose-dependently inhibited contrac-
tion in centrally derived fibroblasts from control subjects
(p < 0.05) and distally derived fibroblasts from both con-
trol subjects (p <0.01) and COPD patients (p < 0.001)
(see Table 2 and Figure 5 B and D). The inhibitory effect
of Y27632 (10 μM) was next compared to the effect of
blebbistatin (50 μM). After 24 hour of incubation, the in-
hibitory effect of Y27632 (10 μM) compared to blebbista-
tin (50 μM) was significantly greater in fibroblasts from
COPD patients (0.90 ± 0.07) than from control subjects
(0.60 ± 0.07) (p < 0.05) (Figure 5 E). This result suggests
that contraction was to a higher extent dependent on the
activity of ROCK1 in distally derived fibroblasts from
COPD patients compared to from control subjects.
In vivo expression of ROCK1 in fibroblasts
Immunohistochemistry was used to identify the presence
of ROCK1-positive fibroblasts in tissue sections from
COPD patients. Since there are few markers that are ex-
clusive for fibroblasts we first evaluated the immunos-
taining of antibodies against ROCK1, vimentin and
prolyl-4 hydroxylase in the submucosa of bronchioles, a
location where fibroblasts normally can be found. Immu-
noreactivity for ROCK1 was identified in bronchiolar epi-
thelial cells, in smooth muscle cells and, in addition, in
elongated, spindle-shaped cells located in the lamina pro-
pria that is likely to be fibroblasts (Figure 6 A). Im-
munoreactivity for vimentin was mainly identified in
smooth muscle cells and in subepithelial fibroblast-like
cells (Figure 6 B). Prolyl-4 hydroxylase immunoreactivity
was identified in bronchiolar epithelial cells, in globular
alveolar cells that are likely to be type II pneumocytes as
has previously described [21] and in subepithelial
fibroblast-like (Figure 6 C). As shown in Figure 7 A-C
there were elongated, fibroblast-like cells double-positive
for vimentin and ROCK1 in the bronchiolar submucosa.
Figure 7 D-F show that double-positive cells also could
be found in the alveolar parenchyma. Additionally, large
rounded cells with a punctuated staining pattern for the
Figure 4 Immunostaining of fibroblasts from COPD patients. Isolated fibroblasts from control subjects and COPD patients were
immunostained to verify their expression of ROCK1 (A) and the mesenchymal markers Vimentin (B) and Prolyl-4 hydroxylase (C). The control
stainings in the absence of primary antibodies for ROCK1 are shown in (D), for vimentin in (E) and for prolyl-4 hydroxylase in (F). Scale bars
represent 50 μm.
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chyma (Figure 7 C and F). These cells are likely to be al-
veolar macrophages.
Discussion
In this study we show that distally derived fibroblasts
from patients with severe COPD are more contractile
than fibroblasts from control subjects. The enhanced
contractility is dependent on ROCK1 expression and
function, as cells from COPD patients have a higher ex-
pression of ROCK1 and contraction was inhibited by the
ROCK1 inhibitor Y27632. Finally, staining of tissue sec-
tions from COPD patients showed the presence of
ROCK1 expressing fibroblasts-like cells in small airways
and in alveolar parenchyma which suggests that the
observed alterations may be relevant in vivo. We suggest
that, in the COPD lung, factors in the deteriorating en-
vironment trigger differentiation of fibroblasts into a
contractile phenotype. This alteration may affect the
elastic dynamics of small airways and the parenchyma in
late stages of COPD.Table 2 Dose–response of Y27632 and blebbistatin
Y27632
Untreated† 10 μM†
Central Control (n = 6) 0,77 0,89 *
COPD (n = 3) 0,73 0,89
Distal Control(n = 6) 0,72 0,82
COPD (n = 7) 0,51 0,87 **
†Values show gel contraction after 24 hours compare to initial area at 0 hours.
* p < 0.05 compared to untreated cells, ** p < 0.01 compared to untreated cells, ***ROCK1 has been shown to be a central player in the
formation of stress fibers [22,23]. It mediates this via
multiple mechanisms which result in phosphorylation of
myosin light chain [24-26]. Several studies have sug-
gested the Rho/ROCK pathway to be involved in the
cellular response to increased matrix stiffness by pro-
moting myofibroblast differentiation and the forma-
tion of stress fibers [27,28]. In an elegant study Liu
et. al. showed that increasing matrix stiffness induced
the transition from a quiescent fibroblast phenotype
into an active myofibroblast-like phenotype [13]. The
transition was suggested to be regulated by the rela-
tive balance of the expression of COX-2/prostaglan-
din E2 and Rho/ROCK. However, emphysema is
characterized by hyperinflation and degradation ra-
ther than fibrotic deposition of the extracellular
matrix as is the case in fibrotic pulmonary diseases
such as cystic fibrosis and idiopathic pulmonary fi-
brosis. In addition, the inflammatory process is dif-
ferent in these diseases compared to COPD, which
may suggest that there are different mechanisms thatblebbistatin
1 μM† 0.1 μM† 50 μM† 5 μM†
0,79 0,68 0,94 * 0,76
0,84 0,80 0,93 0,85
0,70 0,70 0,91 ** 0,71
0,55 0,59 0,93 *** 0,63
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Figure 5 The effect of ROCK on fibroblast contraction. The influence of ROCK1 on the contractile potential of isolated fibroblasts was
investigated using collagen contraction gels. Cells were pre-treated with different concentration of the ROCK inhibitor Y27632 or the myosin II
inhibitor blebbistatin for 1 hour and contraction was monitored as the gel areas after 24 hours compared to the initial gel areas. Paired
comparison of centrally derived fibroblasts (A) or distally derived fibroblasts (C) from control subjects and COPD patients with and without
Y27632 after 24 hours incubation. (B) paired comparison of centrally derived fibroblasts or distally derived fibroblasts (D) from control subjects
and COPD patients with and without the myosin II inhibitor:blebbistatin after 24 hours incubation. (E) Comparison of the inhibitory effects of
Y27632 and blebbistatin calculated as (Y27632-untreated) / (blebbistatin-untreated) after 24 hours incubation for distally derived fibroblasts. (F)
Cytotoxicity of the used antagonists shown as viability as determined by trypan blue exclusion after 24 hours exposure. Open symbols represents
fibroblasts isolated from lung explants and closed symbols fibroblasts isolated from lung biopsies. *P < 0.05, **P < 0.01, *** < 0.001.
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contractile phenotype [29-31].
In conflict with our data, Togo et al. reported that
fibroblasts from moderate to severe COPD patients have
reduced repair capabilities defined as an attenuated po-
tential to contract and migrate [32]. The authors partially
explained the altered phenotype by enhanced expression
of COX-2/PGE2 and partially by unresponsiveness to
TGF-β1. We have in a previous study used cells isolated
from the same donors as in the present study to examine
the fibroblast production of different proteoglycans [17].
The data showed that TGF-β1 induced a similar increase
in the production of versican, perlecan, and biglycan in
fibroblasts from both COPD patients and control sub-
jects, which suggests that the TGF-β1 response in thisrespect was not affected. One explanation to the oppos-
ing data may be differences in the study groups. While
Togo et al. investigated fibroblasts from patients with
moderate to severe COPD (FEV1 % ranging from 19–67
with the mean 44%) all of our patients had very severe
COPD (FEV1 % ranging from 14–24 with the mean 20%).
The deviating data may thus indicate that different fibro-
blast repair mechanisms are activated in lungs from dif-
ferent disease stages.
The differentiation of fibroblasts into myofibroblasts is
accompanied by enhanced expression of α-SMA which
is incorporated into stress fibers [14]. Stress fibers that
contain α-SMA generate more contractile force than
normal stress fibers that only contain β- and γ-actin
[33]. In the present study there was no significant
Figure 6 Fibroblast and ROCK1 staining in lung sections from
COPD patients. Representative micrograph from one COPD patient
that show immunostaining with antibodies against ROCK1, vimentin
and prolyl-4 hydroxylase. Antibodies were visualized by DAB (shown
in brown) and sections were counterstained with Mayer’s
hematoxylin, which stains cell nuclei blue. (A) showsROCK1 staining.
Asterisks indicate the bronchiolar epithelium. Smooth muscle cells
are indicated by open arrowheads. (B) shows vimentin staining.
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http://www.translational-medicine.com/content/10/1/171difference in expression of α-SMA between fibroblasts
from COPD patients and control subjects although the
contractile capability differed. However, contractile force
is generated both by α-SMA and the Rho/ROCK path-
way, and the two cell types had similar expression of α-
SMA but fibroblasts from COPD patients had higher ex-
pression of ROCK1 which may explain the difference.Open arrowhead show smooth muscle cells. (C) shows prolyl-4
hydroxylase staining. Asterisks show immuno-positive bronchiolar
epithelial cells. Alveolar type II cells are indicated by open
arrowheads. Inserts show subepithelial, elongated, spindle-like
immuno-positive cells (indicated by closed arrowheads). Scale bars
represent 50 μm of the larger image and 10 μm on inserts.Recently, it was suggested that there are unique fibro-
blast populations in central airways and in the lung par-
enchyma [15,17,18]. Distally derived fibroblasts have
been shown to have higher α-SMA expression than cen-
trally derived fibroblasts [16]. In the present study there
was a trend that distally derived fibroblasts had higher
expression of α-SMA than centrally derived fibroblasts
both from control subjects and COPD patients. However
we recorded a difference in the expression of ROCK1
between centrally and distally derived fibroblasts both
from control subjects. In addition, in severe COPD
patients we could extend this comparison to also include
contractile potential.
In the current study we identified fibroblast-like cells
that were immuno-positive for fibroblast markers and
ROCK1 in small airways and in the alveolar parenchyma.
These data suggests that the present functional in vitro
data also may be relevant in vivo. The altered phenotype
may be a compensatory mechanism to the loss of elastic
fibers and specific extracellular matrix molecules, as has
been reported in the parenchyma of COPD patients [34].
The primary fibroblasts used in the present study
came from two sources. Fibroblasts from COPD patients
were isolated from lung explants while control fibro-
blasts were obtained from both biopsies and from lung
explants from control subjects. When isolating distal
fibroblasts from explants there is always a risk of con-
tamination with small airways although care was taken
to avoid it. However, we could not see any skewness due
to the different isolation sources in the assays we used
with exception for the RhoA western blot where the
controls were stratified due to origin of fibroblasts. Fur-
thermore, it has been shown that glucocorticoids may
enhance fibroblast gel contraction. All COPD patients in
this study were taking glucocorticoids on regular basis
and we can therefore not exclude that some of the inves-
tigated parameters were affected by these drugs [35].
The two groups were poorly age-matched, and it cannot
be excluded that some of the observed results were a re-
sult of these differences. However, to account for the poor
Figure 7 Double staining of vimentin and ROCK1. Immunostaining for ROCK1 (A and D) and vimentin (B and E) in COPD tissue sections. Cell
nuclei are visualized by DAPI staining, shown in blue. (C) and (F) show merged images. (A), (B) and (C) show a small airway and (D), (E) and (F)
alveolar parenchyma. Inserts show cells positive for both ROCK1 and vimentin with fibroblast-like morphology as indicated by closed arrowheads.
Open arrowheads show rounded double-positive cells that are likely to be alveolar macrophages. Scale bars represent 50 μm of the larger image
and 10 μm on inserts.
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http://www.translational-medicine.com/content/10/1/171age-match between the study groups, fibroblasts from
donor lungs (from control subjects similar in age as the
COPD patients) were also included and these cells did
not differ from the other control cells in the assays used.
The COPD patients in the present study were all ex-
smokers while the controls were non-smokers (except
for one subject). As have been shown by Wang et al.
cigarette smoke may induce contraction of high-density
primary fibroblasts cultures and it can therefore not be
ruled out that some of the observed changes in the
present study are a result of chronic inflammation
induced by smoking [36].
Conclusions
In summary, in this study we report that fibroblasts iso-
lated from the parenchyma from patients with severe
COPD have a more contractile phenotype. This altered
phenotype was dependent on ROCK1, as ROCK1 ex-
pression was found to be increased and the selective
ROCK-inhibitor Y27632 blocked contraction. This alter-
ation may be important for the elastic dynamic in severe
stages of COPD.Abbreviations
COPD: Chronic obstructive pulmonary disease; ROCK1: Rho-associated coiled-
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